Amlodipine induced chylous ascites in a patient undergoing peritoneal dialysis: A case report
Keywords:
Amlodipine, Chylous Ascites, Peritoneal dialysis
Abstract
Amlodipine besilate, long-acting dihydropyridine type calcium channel blocker is widely used as an antihypertensive agent. In some reports, long-acting dihydropyridine type calcium channel blockers caused chylous ascites in peritoneal dialysis patients but none of the cases was associated with use of amlodipine. Here, we describe a case of a patient who was on peritoneal dialysis for CKD and developed chylous ascites after he was prescribed amlodipine for hypertension. The chylous ascites resolved after cessation of amlodipine therapy. The exact mechanism of this phenomenon is still not established although few speculative theories are known. A thorough clinical, laboratory and imaging assessment of this patient didn’t suggest any alternative diagnosis. We conclude that this patient’s chylous ascites was amlodipine related and physicians should be aware of the possibility of ascites due to the administration of long-acting dihydropyridine type calcium channel blockers particularly in those undergoing peritoneal dialysis.References
1. Laterre PF, Dugernier T, Reyneart MS. Chylous Ascites: diagnosis, causes and management. Acta Gastroenterol Belg, 2000, July-Sept, 63(3): 260-63.
2. Said A. Al-Busafi, Ghali P, Deschênes M and Wong P. “Chylous Ascites: Evaluation and Management,” ISRN Hepatology- 2014, Article ID 240473, 10 pages, 2014. doi:10.1155/2014/240473
3. Tsao YT, Chen WL. Calcium channel blocker–induced chylous ascites in peritoneal dialysis. Kidney Int, 2009; 75: 868.
4. Graice R, Bargman JM. Calcium channel blocker–induced chylous ascites in peritoneal dialysis. Kidney Int, 2010; 77:165.
5. Yoshimoto K, Saima S, Nakamura Y, Nakayama M, Kubo H, Kawaguchi Y, et al. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis. Clin Nephrol, 1998; 50: 90–93.
6. Yoshimoto K, Saima S, Echizen H, Nakamura Y, Ishizaki T. A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1993; 40:114–17
7. Teitelbaum I. Cloudy peritoneal dialysate: it’s not always infection. Peritoneal Dialysis: A Clinical Update. Volume 150. Basel, Switzerland: Karger AG; 2006: 187–94.
8. Yang WS, Huang JW, Chen HW, Tsai TJ, Wu KD. Lercanid¬ipine-induced chylo-peritoneum in patients on peritoneal dialysis. Perit Dial Int, 2008; 28: 632–36.
2. Said A. Al-Busafi, Ghali P, Deschênes M and Wong P. “Chylous Ascites: Evaluation and Management,” ISRN Hepatology- 2014, Article ID 240473, 10 pages, 2014. doi:10.1155/2014/240473
3. Tsao YT, Chen WL. Calcium channel blocker–induced chylous ascites in peritoneal dialysis. Kidney Int, 2009; 75: 868.
4. Graice R, Bargman JM. Calcium channel blocker–induced chylous ascites in peritoneal dialysis. Kidney Int, 2010; 77:165.
5. Yoshimoto K, Saima S, Nakamura Y, Nakayama M, Kubo H, Kawaguchi Y, et al. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis. Clin Nephrol, 1998; 50: 90–93.
6. Yoshimoto K, Saima S, Echizen H, Nakamura Y, Ishizaki T. A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1993; 40:114–17
7. Teitelbaum I. Cloudy peritoneal dialysate: it’s not always infection. Peritoneal Dialysis: A Clinical Update. Volume 150. Basel, Switzerland: Karger AG; 2006: 187–94.
8. Yang WS, Huang JW, Chen HW, Tsai TJ, Wu KD. Lercanid¬ipine-induced chylo-peritoneum in patients on peritoneal dialysis. Perit Dial Int, 2008; 28: 632–36.
Published
2016-08-18
Issue
Section
Case Reports
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).